GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » UCB SA (WBO:UCB) » Definitions » Pre-Tax Income

UCB (WBO:UCB) Pre-Tax Income : €441 Mil (TTM As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is UCB Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. UCB's pretax income for the six months ended in Dec. 2023 was €40 Mil. Its pretax income for the trailing twelve months (TTM) ended in Dec. 2023 was €441 Mil. UCB's pretax margin was 1.50%.

During the past 13 years, UCB's highest Pretax Margin was 21.91%. The lowest was 3.32%. And the median was 17.44%.


UCB Pre-Tax Income Historical Data

The historical data trend for UCB's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

UCB Pre-Tax Income Chart

UCB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Pre-Tax Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 960.00 880.00 1,226.00 511.00 441.00

UCB Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Pre-Tax Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 583.00 481.00 30.00 401.00 40.00

Competitive Comparison of UCB's Pre-Tax Income

For the Biotechnology subindustry, UCB's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


UCB's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, UCB's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where UCB's Pre-Tax Income falls into.



UCB Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

UCB's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=633+0+-144+27+-75
=441

UCB's Pretax Income for the quarter that ended in Dec. 2023 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=147+0+-81+0+-26
=40

Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €441 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


UCB  (WBO:UCB) Pre-Tax Income Explanation

UCB's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as

Pretax Margin=Pretax Income/Revenue
=40/2663
=1.50%

During the past 13 years, UCB's highest Pretax Margin was 21.91%. The lowest was 3.32%. And the median was 17.44%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


UCB Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of UCB's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.


UCB (WBO:UCB) Business Description

Address
Allee de la Recherche, 60, Brussels, BEL, B-1070
UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), and Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome).

UCB (WBO:UCB) Headlines

No Headlines